Dr. Kathleen Anne Welsh-Bohmer is a distinguished Professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine, with secondary appointments in Neurology and Psychology and Neuroscience. She serves as the Director of Outreach and Recruitment Core of the Duke/UNC Alzheimer Disease Research Center and is a member of the Duke Clinical Research Institute and Duke Institute for Brain Sciences. Dr. Welsh-Bohmer earned her Ph.D. from the University of Virginia in 1985. Her research career has focused on developing effective prevention and treatment strategies to delay the onset of cognitive disorders in later life. From 2006 through 2018, she directed the Joseph and Kathleen Bryan Alzheimer's Center in the Department of Neurology and oversaw neuropsychology operations for the global TOMMORROW clinical trial. Currently, she directs the Alzheimer's disease therapeutic area within the Duke Clinical Research Institute and collaborates with VeraSci to develop digital cognitive assessment tools for early Alzheimer's disease detection. Her research spans multiple domains of Alzheimer's disease and cognitive aging, with particular emphasis on developing reliable digital cognitive assessment tools informed by neuroscience and technology advances. Her work addresses critical gaps in early pre-clinical Alzheimer's disease detection and has significant implications for both clinical practice and accelerating global clinical trials for Alzheimer's prevention. She has made substantial contributions to understanding genetic factors in cognitive decline, particularly through her work with the TOMM40 and APOE genes. Analysis of her recent publications reveals a strong focus on advancing diagnostic methods, understanding genetic risk factors, developing digital assessment tools, and examining cognitive trajectories in aging populations. Her research bridges basic neuroscience with clinical applications, with increasing emphasis on technology-enabled assessment methods and precision medicine approaches to Alzheimer's disease. Dr. Welsh-Bohmer has been actively involved in numerous major research initiatives including the Cache County Memory Study and the TOMMORROW clinical trial. Her collaborative approach spans multiple institutions and research domains, reflecting the interdisciplinary nature of modern Alzheimer's research. She has contributed significantly to understanding how vascular factors, genetic markers, and lifestyle factors influence cognitive aging and dementia risk. Her laboratory and research team focus on developing and validating cognitive assessment tools that can detect subtle changes in cognitive function before clinical symptoms of dementia emerge. This work involves close collaboration with technology companies, clinicians, and basic scientists to create assessment methods that are both scientifically rigorous and practical for clinical use.
